BioNTech SE (ADRs)
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
25.71%
Market Cap
19.26 Bil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-4.70 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 77.4 G | 0 Units |
| PRICE DETERMINATION TIME | 06/04/2026 / 08:17:39 PM | |
| DAILY VOLUME (UNITS) | 14,102 | |
| DAILY HIGH / LOW | 78 | 76.35 |
| PREV. DAY'S PRICE | 76.15 | (06/03) |
| CHANGE DAY BEFORE | +1.25 | 1.64 % |
| 52 WEEK HIGH / LOW | 105 (01/22) | 68.35 (03/10) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | -4.84 | -4.15 | -4.70 | -2.77 | 3.87 |
| DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| DIVIDEND YIELD IN % | - | - | 0.00 % | 0.00 % | 0.00 % |
| DIVIDEND GROWTH IN % | - | - | - | - | - |
| PRICE - EARNINGS RATIO | - | - | - | - | 25.25 |
| PRICE - BOOK RATIO | - | - | 1.06 | 1.36 | 1.12 |
| PRICE - SALES RATIO | - | - | 7.10 | 9.21 | 6.20 |
| PRICE - CASH FLOW RATIO | - | - | 44.71 | 121.93 | 4.41 |
Master Data
| WKN | A2PSR2 |
| ISIN | US09075V1026 |
| SYMBOL | 22UA |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | BIONTECH SE SPON. ADRS 1 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 252.88 Mil. |
| MARKET CAPITALISATION | 19.26 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -4.63 % | -13.81 % | -12.07 % | -7.98 % | -25.71 % | -24.57 % | -57.29 % | -6.39 % |
| HIGH | 84.40 | 85.65 | 96.10 | 105.00 | 105.00 | 124.50 | 396.50 | 105.00 |
| LOW | 75.85 | 75.35 | 68.35 | 68.35 | 68.35 | 68.35 | 68.35 | 68.35 |
Dividend
per share
BIONTECH SE SPON. ADRS 1 does not deliver dividend information
Company profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Structured products for BioNTech SE (ADRs)
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
(in 61 days)
08/04/26Q2 2026 Earnings Release
(in 61 days)
08/04/26Q2 2026 Earnings Call
(in 152 days)
11/03/26Q3 2026 Earnings Call
(in 152 days)
11/03/26Q3 2026 Earnings Release
(in 299 days)
03/30/27Q4 2026 Earnings Release